AUY922 for Advanced ALK-positive NSCLC

NCT01752400 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

6

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: AUY922

Sponsor

Massachusetts General Hospital